血液MALT1反映了老年慢性阻塞性肺病患者的急性恶化风险和炎症
Cui Liu1, Jinsong Zhu1, Lei Zhao1
1Department of Respiratory Medicine, Cangzhou People's Hospital, Cangzhou 061000, China.
Biomarkers in medicine
|August 13, 2024
概括
血液MALT1水平可以帮助预测慢性阻塞性肺病 (COPD) 的老年患者急性恶化. 较高的MALT1表明风险和炎症增加,有助于对COPD恶化的风险评估.
科学领域:
- 免疫学 免疫学 免疫学
- 肺部病理学 肺部病理学
- 生物标志物研究 生物标志物研究
背景情况:
- 慢性阻塞性肺病 (COPD) 是发病和死亡的主要原因,特别是在老年人中.
- 急性恶化严重恶化了COPD患者的预后,增加了COPD患者的医疗费用.
- 确定可靠的生物标志物来确定恶化风险对于主动管理至关重要.
研究的目的:
- 评估血液MALT1 (粘膜相关淋巴组织1) 作为老年COPD患者急性恶化风险的生物标志物的潜力.
- 为了将MALT1水平与COPD的临床参数和疾病严重程度相关联.
主要方法:
- 招募了176名老年COPD患者 (年龄大于60岁) 的队列.
- 分析了血液样本以量化MALT1水平.
- 进行了统计分析,以评估MALT1和恶化状态,肺功能测试和COPD严重程度分期之间的关系.
主要成果:
- 与患有稳定疾病的患者相比,患有急性COPD恶化患者的MALT1水平显著升高 (p < 0.001).
- 在恶化的患者中,MALT1与FEV1/FVC比率 (p = 0.024) 和预测的FEV1% (p = 0.002) 有负相关性.
- 马尔特1水平与全球慢性阻塞性肺病倡议 (GOLD) 阶段 (p = 0.005) 有正相关,表明严重程度更高.
结论:
- 血液MALT1是老年COPD患者急性恶化风险增加的有价值指标.
- 在这个人群中,MALT1水平升高与系统性炎症增加和肺功能低下有关.
- 马尔特1可能代表一种新的治疗标或诊断标记,用于管理COPD恶化.
相关概念视频
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.7K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.7K
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
2.7K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
2.7K
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
2.8K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
2.8K
01:22Chronic Obstructive Pulmonary Disease
1.2K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.2K
01:26COPD: Management Using Bronchodilators and Corticosteroids
192
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
192
01:29Acute Respiratory Failure-V
126
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
126